Update on Global Access to Sotrovimab for COVID-19Patients

Vir Biotechnology, Inc. (the "Company") today announced significant progress increasing global patient access to sotrovimab, an investigational monoclonal antibody treatment for COVID-19 developed in partnership with GlaxoSmithKline. To date, binding agreements have been received for the sale of more than 420,000 doses of sotrovimab worldwide, including a portion of those procured by the U.S. government. In addition, more than 220,000 doses have been reserved through other agreements. The companies continue discussions with governments around the world for additional agreements that can support the ongoing pandemic response.

Forward-Looking Statements

This Current Report on Form 8-Kcontains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "plan," "potential," "aim," "promising" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this Current Report on Form 8-K.Forward-looking statements contained in this Current Report on Form 8-Kinclude a statement by the Company's regarding discussions with governments around the world for the purchase of sotrovimab in the treatment of COVID-19.Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including the section titled "Risk Factors" contained therein. Except as required by law, the Company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Attachments

  • Original document
  • Permalink

Disclaimer

Vir Biotechnology Inc. published this content on 29 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 September 2021 21:21:08 UTC.